Silica Magnetic Beads for Cell-Free DNA Extraction and Liquid Biopsy

Silica Magnetic Beads for cfDNA Extraction: Quick Answer

Silica magnetic beads isolate cell-free DNA, or cfDNA, through a reversible bind–wash–elute process.

A biological fluid such as plasma is first treated to release short DNA fragments from proteins, vesicles and other sample components. Binding salts and, in many systems, alcohol create conditions that allow cfDNA to adsorb onto the silica-coated surfaces of magnetic beads.

An external magnet collects the bead–DNA complex. Proteins, salts, lipids and potential amplification inhibitors are removed during washing. Water or a low-salt elution buffer then releases the purified cfDNA into a small final volume.

The basic workflow is:

1. Collect and stabilize the sample;

2. Prepare cell-depleted plasma or another biofluid;

3. Digest proteins and release cfDNA;

4. Add binding buffer and silica magnetic beads;

5. Allow fragmented DNA to bind;

6. Collect the beads magnetically;

7. Wash away contaminants;

8. Remove residual alcohol;

9. Elute the concentrated cfDNA;

10. Analyze it using PCR, digital PCR, sequencing or another molecular method.

Magnetic bead-based cfDNA methods are available for manual and automated workflows. Commercial systems support sample types including plasma, serum, urine and cerebrospinal fluid, although the exact validated matrices depend on the individual product.

The bead is only one part of the extraction system. Performance also depends on:

• Blood collection;

• Sample stabilization;

• Plasma preparation;

• Protein digestion;

• Binding chemistry;

• Fragment-size recovery;

• Wash efficiency;

• Elution volume;

• Magnetic separation;

• Downstream assay requirements.

What Is Cell-Free DNA?

Cell-free DNA is DNA found outside intact cells in blood or other biological fluids.

It may originate from normal or abnormal biological processes involving:

• Cell turnover;

• Apoptosis;

• Necrosis;

• Active release;

• Tissue injury;

• Pregnancy;

• Transplanted organs;

• Tumors.

cfDNA can be found in biofluids including:

• Plasma;

• Serum;

• Urine;

• Cerebrospinal fluid;

• Saliva;

• Pleural fluid;

• Other body fluids.

The concentration, fragment distribution and biological origin of cfDNA vary among individuals and sample types.

Many circulating cfDNA fragments reflect nucleosome-associated fragmentation, but cfDNA is not limited to a single fragment length. Commercial extraction systems increasingly evaluate recovery across typical nucleosomal regions, shorter fragments and longer DNA species.

cfDNA vs ccfDNA vs ctDNA

The terms are related but not identical.

cfDNA

Cell-free DNA is the broad term for DNA fragments found outside intact cells in a biological fluid.

ccfDNA

Circulating cell-free DNA generally refers to cfDNA circulating in blood.

Some manufacturers use “ccfDNA” to distinguish blood-derived circulating DNA from cfDNA found in other body fluids.

ctDNA

Circulating tumor DNA is the tumor-derived fraction of circulating cfDNA.

A plasma sample can contain DNA originating from:

• Normal blood cells;

• Other normal tissues;

• Tumor cells;

• Transplanted organs;

• Fetal or placental tissue during pregnancy.

Therefore:

All ctDNA is cfDNA, but not all cfDNA is ctDNA.

Extracting total cfDNA does not automatically enrich the tumor-derived fraction. The proportion of ctDNA depends on the biological sample and cannot usually be determined from total DNA concentration alone.

Is Liquid Biopsy the Same as cfDNA Testing?

No.

Liquid biopsy is a broader category of molecular analysis performed using blood or another body fluid instead of a conventional solid-tissue biopsy.

Potential liquid-biopsy analytes include:

• cfDNA;

• ctDNA;

• Cell-free RNA;

• Circulating tumor cells;

• Extracellular vesicles;

• Proteins;

• Metabolites;

• Other circulating biomarkers.

cfDNA extraction is therefore one part of some liquid-biopsy workflows, but liquid biopsy is not synonymous with cfDNA isolation.

A complete liquid-biopsy workflow may include:

1. Sample collection;

2. Plasma or biofluid preparation;

3. cfDNA extraction;

4. Quantification and quality control;

5. Library preparation or amplification;

6. Molecular detection;

7. Bioinformatic interpretation.

For clinical use, the complete workflow requires appropriate analytical and regulatory validation. A research-use magnetic bead or extraction method should not be represented as a diagnostic product without such validation.

Why cfDNA Extraction Is More Challenging Than Genomic DNA Extraction

cfDNA extraction is challenging because the target is often:

• Present at low concentration;

• Highly fragmented;

• Distributed across a wide fragment-size range;

• Surrounded by abundant proteins;

• Mixed with genomic DNA;

• Variable between samples;

• Sensitive to preanalytical handling.

By contrast, a genomic DNA extraction may begin with millions of cells containing relatively large amounts of DNA.

The cfDNA method must recover a limited number of short molecules from a comparatively large volume of biofluid.

Important challenges include:

Low concentration

cfDNA may be present at concentrations near the detection limits of common absorbance-based quantification methods.

Large sample volume

A laboratory may process several milliliters of plasma to obtain enough cfDNA for downstream analysis.

Short fragment sizes

The method must efficiently retain short fragments while avoiding size-dependent loss.

Genomic DNA contamination

White blood cell disruption before plasma separation can release high-molecular-weight genomic DNA, diluting the relative abundance of the target cfDNA fraction.

Sample variability

Protein content, hemolysis, plasma quality, collection tubes and storage conditions can vary among samples.

Commercial and research comparisons show that extraction methods can differ in total yield, fragment recovery and size bias. Consequently, the highest measured total DNA concentration does not necessarily indicate the best cfDNA method.

Why Silica Magnetic Beads Are Used for cfDNA Isolation

Silica magnetic beads combine a nucleic acid-binding surface with a magnetically movable solid phase.

Key advantages include:

• High accessible surface area;

• Compatibility with short DNA fragments;

• Adjustable bead quantity;

• Flexible sample input;

• Small-volume elution;

• No centrifugation during magnetic separation;

• Manual and automated compatibility;

• Scale-up to multiwell formats.

QIAGEN identifies both magnetic beads and silica membrane columns as established cfDNA purification formats. Magnetic beads are particularly suitable when the workflow needs automation or scalable processing.

Solution-phase contact

Magnetic beads can be dispersed throughout the lysed sample.

This allows the silica surface to contact DNA throughout the liquid rather than depending on the sample passing through a fixed membrane.

Adjustable solid-phase quantity

The amount of bead can be adjusted according to:

• Plasma input volume;

• Expected DNA quantity;

• Buffer composition;

• Required recovery;

• Automation format.

Flexible automation

Magnetic bead workflows can be used on:

• Manual tube magnets;

• Magnetic rod extractors;

• Automated plate magnets;

• Liquid-handling workstations;

• Prefilled cartridge systems.

Low-volume elution

A small elution volume can increase cfDNA concentration for PCR or NGS.

However, reducing the volume too far may lower total recovery or make complete bead resuspension difficult.

How Silica Magnetic Beads Bind Short DNA Fragments

Silica surfaces contain silanol groups.

Under ordinary aqueous conditions, DNA and silica are hydrated and generally carry negative charges. Suitable binding buffers alter the ionic and hydration environment.

The binding system commonly uses:

• Chaotropic salts;

• High ionic strength;

• Alcohol;

• Controlled pH;

• Reduced water activity.

These conditions reduce hydration and electrostatic repulsion, allowing DNA fragments to adsorb reversibly onto the silica surface.

During washing, the buffer maintains DNA binding while proteins and other contaminants are removed.

During elution, low-salt buffer or water rehydrates the DNA and silica surface, weakening their interaction and returning the cfDNA to solution.

The bead surface does not inherently recognize tumor DNA or a specific DNA sequence.

Standard silica magnetic beads capture DNA according to the physical and chemical binding conditions.

Sequence or mutation specificity is introduced later through:

• PCR primers;

• Hybridization probes;

• Targeted sequencing;

• Methylation assays;

• Other molecular detection methods.

Complete cfDNA Extraction Workflow

Step 1: Collect and Stabilize the Blood Sample

The extraction workflow begins at blood collection.

Important variables include:

• Collection-tube type;

• Anticoagulant;

• Time before plasma separation;

• Storage temperature;

• Transport conditions;

• Mechanical agitation;

• Tube fill volume.

When standard anticoagulant tubes are used, delayed processing can permit white blood cell disruption and genomic DNA release.

Specialized stabilization tubes may permit longer transport or processing windows, but the tube manufacturer’s validated instructions must be followed.

Sample collection conditions can affect both total DNA concentration and the proportion of short cfDNA relative to contaminating genomic DNA.

Step 2: Prepare Cell-Depleted Plasma

Whole blood should be processed to remove cells before cfDNA extraction.

A plasma-preparation workflow may include:

1. Initial centrifugation to separate plasma;

2. Careful transfer without disturbing the cellular layer;

3. A second clarification step to remove residual cells or debris;

4. Immediate extraction or validated plasma storage.

Plasma is generally preferred to serum for ctDNA-related analysis because clotting and cell disruption during serum preparation can increase genomic DNA contamination. QIAGEN likewise recommends plasma as the preferred sample for many cfDNA analyses.

Residual cells can release large genomic DNA fragments during storage or freeze–thawing.

A high total DNA yield caused by cellular contamination may reduce the relative representation of ctDNA and complicate downstream interpretation.

Step 3: Digest Proteins and Release cfDNA

cfDNA may be associated with:

• Histones;

• Nucleosomes;

• Plasma proteins;

• Lipoproteins;

• Extracellular vesicles;

• Other molecular complexes.

The lysis or digestion step should release accessible DNA while reducing protein contamination.

A typical system may use:

• Proteinase K;

• Detergents;

• Chaotropic salts;

• Controlled incubation;

• Mixing.

QIAGEN recommends an extraction workflow containing a lysis step capable of releasing nucleic acids associated with proteins, lipids and vesicles.

Incomplete protein digestion may lead to:

• Lower recovery;

• Poor binding;

• Bead aggregation;

• Increased PCR inhibition;

• Variable results.

Step 4: Create the Binding Conditions

Add the validated binding buffer and, where required, alcohol.

Critical parameters include:

• Salt concentration;

• Alcohol concentration;

• pH;

• Sample-to-buffer ratio;

• Total reaction volume;

• Bead quantity;

• Mixing time.

Conditions must support efficient recovery of the desired fragment-size range.

A buffer optimized for long genomic DNA may not provide equivalent recovery of short cfDNA.

Step 5: Bind cfDNA to Silica Magnetic Beads

Fully resuspend the magnetic beads before dispensing.

Add the validated bead quantity and mix throughout the binding period.

The binding step should provide sufficient contact among:

• cfDNA fragments;

• Silica surfaces;

• Binding reagents.

NEB’s current cfDNA troubleshooting guidance emphasizes sufficient mixing and incubation between the sample and bead-binding mixture to establish effective cfDNA binding conditions.

Poor mixing can produce:

• Low recovery;

• Inconsistent short-fragment capture;

• Variation among wells;

• Higher extraction failure near the detection limit.

Step 6: Magnetically Separate the Beads

Apply the magnetic field and allow the beads to collect fully.

Collection time depends on:

• Particle size;

• Magnetic content;

• Bead concentration;

• Liquid volume;

• Sample viscosity;

• Vessel geometry;

• Magnet strength.

Remove the supernatant carefully without aspirating the bead pellet or ring.

During method development, the binding supernatant can be tested to determine whether cfDNA remained unbound.

Step 7: Wash Away Proteins and Inhibitors

Add the validated wash buffer and fully resuspend the beads where required.

Washing should remove:

• Proteins;

• Lipids;

• Chaotropic salts;

• Detergents;

• Anticoagulants;

• Other plasma-derived inhibitors.

Multiple wash buffers may be used for different purposes.

The number and volume of washes should be sufficient to achieve downstream compatibility without unnecessarily increasing target or bead loss.

Step 8: Remove Residual Alcohol

Alcohol-containing wash buffer must be removed before elution.

Residual ethanol or isopropanol can inhibit:

• PCR;

• Digital PCR;

• Ligation;

• Library preparation;

• Sequencing reactions.

A controlled drying period may be required.

Do not over-dry the beads. Excessive drying can form a compact pellet that is difficult to redisperse and may reduce cfDNA elution.

Step 9: Elute Concentrated cfDNA

Add nuclease-free water or a validated low-salt elution buffer.

Mix and incubate under controlled conditions.

Important variables include:

• Elution volume;

• Buffer pH;

• Temperature;

• Incubation time;

• Mixing;

• Bead drying state.

A low elution volume improves concentration but may reduce total recovery.

Commercial cfDNA systems often emphasize low-volume elution because the total DNA amount is limited and downstream reactions may accept only a small input volume.

After elution, collect the beads magnetically again and transfer the eluate without bead carryover.

Plasma vs Serum for cfDNA Extraction

Both plasma and serum contain extracellular DNA, but they are not equivalent sample matrices.

Plasma

Plasma is separated from anticoagulated blood.

Advantages for cfDNA and ctDNA work include:

• Lower risk of DNA release during clot formation;

• Lower background genomic DNA in many workflows;

• Broad use in liquid-biopsy research;

• Compatibility with specialized stabilization tubes.

Serum

Serum is prepared after blood coagulation.

During clotting and processing, cellular disruption can increase the concentration of high-molecular-weight genomic DNA.

This can create the appearance of a higher DNA yield while decreasing the relative proportion of the original circulating cfDNA fraction.

For this reason, plasma is generally preferred for ctDNA and many other cfDNA analyses.

Serum may still be appropriate for a validated application, but it should not automatically be treated as interchangeable with plasma.

How Blood Collection and Plasma Processing Affect cfDNA Quality

Preanalytical handling can influence cfDNA more strongly than small changes in bead quantity.

Important variables include:

• Collection-tube type;

• Time to processing;

• Temperature;

• Centrifugation;

• Residual cell removal;

• Plasma transfer;

• Storage;

• Freeze–thaw cycles.

Delayed processing

Delayed plasma separation may allow leukocytes to break down and release genomic DNA.

Incomplete cell removal

Residual cells or cell fragments may release DNA during storage.

Rough transfer

Disturbing the buffy coat during plasma transfer can increase cellular contamination.

Repeated freeze–thawing

Repeated cycles may affect sample quality and increase variability.

NEB advises following collection-tube instructions and controlling sample handling to preserve the cfDNA fraction and minimize cellular DNA release.

The preanalytical procedure should be standardized before comparing magnetic beads.

cfDNA Fragment Sizes and Nucleosomal Patterns

A large fraction of plasma cfDNA is associated with nucleosome-related fragmentation.

Typical cfDNA profiles may include:

• A major mononucleosomal region;

• Multiples associated with di- and trinucleosomal fragments;

• Shorter fragments below the main peak;

• Longer genomic DNA contamination.

The exact profile depends on:

• Biological source;

• Cell-death mechanism;

• Sample processing;

• Extraction chemistry;

• Library preparation;

• Analytical platform.

The target fragment range should be specified before selecting a magnetic bead.

For example:

• Targeted mutation testing may prioritize the main cfDNA region;

• Fragmentomic studies may require unbiased recovery across a broad size range;

• Some assays may depend on ultrashort DNA;

• Genomic contamination assessment requires detection of long fragments.

Short-Fragment Recovery and Extraction Bias

Extraction bias occurs when a method recovers some fragment sizes more efficiently than others.

Possible causes include:

• Silica surface properties;

• Binding-buffer composition;

• Alcohol concentration;

• Bead quantity;

• Incubation time;

• Wash chemistry;

• Elution conditions.

An extraction system may provide a high total DNA yield but lose shorter fragments or over-recover long genomic DNA.

NEB’s 2026 cfDNA product data specifically compare recovery in the typical 150–300 bp region, below 150 bp and at approximately 50 bp, illustrating the importance of evaluating fragment-specific yield instead of total concentration alone. These figures are manufacturer-generated product data and should be independently confirmed for the intended workflow.

Recommended evaluation tools include:

• Capillary electrophoresis;

• Tape-based fragment analysis;

• qPCR assays with different amplicon lengths;

• Digital PCR;

• Sequencing insert-size analysis;

• Defined fragmented DNA controls.

cfDNA Extraction vs ctDNA Enrichment

cfDNA extraction and ctDNA enrichment are different processes.

cfDNA extraction

The goal is to recover extracellular DNA from the sample.

Standard silica magnetic beads normally recover both:

• Tumor-derived cfDNA;

• Non-tumor cfDNA.

ctDNA enrichment

The goal is to increase the relative detectability of tumor-derived molecules.

Potential enrichment approaches include:

• Targeted hybridization;

• Mutation-specific amplification;

• Methylation-based selection;

• Fragment-size enrichment;

• Molecular barcoding and error suppression;

• Bioinformatic filtering.

A standard silica magnetic bead is not inherently tumor-specific.

A high cfDNA recovery does not guarantee a high ctDNA fraction.

cfDNA Extraction vs SPRI Size Selection

Silica magnetic beads and carboxylated SPRI beads may be used at different stages.

Silica magnetic beads

Usually used to extract cfDNA from plasma or another biological fluid.

Carboxylated SPRI beads

Frequently used after extraction for:

• DNA cleanup;

• Concentration;

• Library purification;

• Fragment-size selection.

Promega has described magnetic bead-based size selection to enrich the characteristic circulating cfDNA region by reducing larger DNA background. This is a post-extraction enrichment method and is not the same as primary silica magnetic bead isolation.

A liquid-biopsy workflow may therefore use:

1. Silica magnetic beads for initial cfDNA extraction;

2. Carboxylated SPRI chemistry for library cleanup or fragment enrichment.

How to Choose Silica Magnetic Beads for cfDNA

Particle Size and Surface Area

Smaller particles may provide more surface area per unit mass.

Potential advantages include:

• More binding sites;

• Efficient contact with low-abundance fragments;

• Flexible low-input recovery.

Potential disadvantages include:

• Slower magnetic collection;

• Greater aspiration risk;

• Higher bead carryover;

• More demanding magnet requirements.

A smaller nominal particle diameter does not automatically guarantee better cfDNA recovery.

Magnetic Response

The bead should collect completely within the available instrument time.

Evaluate magnetic response in:

• Binding buffer;

• Plasma lysate;

• Wash buffer;

• Elution buffer.

A collection time measured only in water may not represent actual extraction performance.

Short-Fragment Binding

Request functional data across defined fragment sizes.

Useful regions may include:

• Below 100 bp;

• 100–150 bp;

• 150–300 bp;

• Above 300 bp;

• High-molecular-weight genomic DNA.

The required recovery profile depends on the downstream assay.

Sedimentation and Redispersibility

The beads should redisperse completely during:

• Initial dispensing;

• Binding;

• Washing;

• Elution.

Rapid sedimentation may cause unequal bead doses during automated plate dispensing.

Poor redispersibility may trap proteins, salts or residual alcohol.

Binding Capacity

Maximum binding capacity is not the main requirement for many cfDNA workflows because total DNA input is low.

More important characteristics may include:

• Low-input recovery;

• Short-fragment recovery;

• Low surface loss;

• Efficient elution;

• Reproducibility.

A bead with extremely high theoretical capacity may not outperform a bead optimized for scarce, fragmented DNA.

Low-Volume Elution

Evaluate whether the beads can be fully resuspended in the desired elution volume.

Too little buffer may:

• Leave part of the pellet uncovered;

• Reduce contact with the silica surface;

• Increase bead carryover risk;

• Reduce total recovery.

Bead Carryover

Residual beads can affect:

• Optical measurements;

• Automated liquid handling;

• PCR;

• Library preparation;

• Integrated detection systems.

A final magnetic clarification may be required.

How Sample Input Volume Affects Extraction

Increasing plasma input can increase the amount of recoverable cfDNA, but it also changes:

• Protein load;

• Reagent requirements;

• Total binding volume;

• Bead quantity;

• Vessel format;

• Magnetic collection;

• Elution concentration.

Commercial systems use different input ranges. For example, Promega lists a plasma workflow for smaller inputs, while QIAGEN and NEB offer systems designed for larger or scalable biofluid volumes.

When scaling from 1 mL to 4 mL or more, do not simply multiply every reagent without testing.

Evaluate:

• Lysis completeness;

• Protein digestion;

• Bead capacity;

• Mixing;

• Magnetic collection;

• Wash efficiency;

• Final concentration.

Manual vs Automated cfDNA Extraction

A manual method should generally be established as a performance benchmark before automation.

Automation should be evaluated against the manual control using:

• Total yield;

• Fragment-specific recovery;

• qPCR or digital PCR;

• Precision;

• Carryover;

• Processing time.

Magnetic Rod Systems vs Liquid-Handling Workstations

Magnetic rod systems

A magnetic rod collects and moves beads between reagent wells.

Critical properties include:

• Fast bead collection;

• Complete release from the rod cover;

• Good wash redispersion;

• Limited liquid carryover.

Liquid-handling workstations

The beads remain in the well while a robot removes and adds liquids.

Critical properties include:

• Uniform bead dispensing;

• Controlled sedimentation;

• Predictable pellet position;

• Low aspiration loss;

• Low bead carryover.

QIAGEN, Promega, Thermo Fisher and NEB all provide automated magnetic bead cfDNA options, but their instrument architectures, sample volumes and reagent systems differ.

A bead validated on one system should not automatically be considered validated on another.

Downstream Applications in Liquid Biopsy

qPCR and Digital PCR

PCR-based methods may be used for:

• Mutation detection;

• Copy-number analysis;

• Methylation assays;

• Targeted quantification;

• Research monitoring.

Extraction quality affects:

• Ct value;

• Detection rate;

• Replicate precision;

• Inhibition;

• Limit-of-detection performance.

Targeted NGS

Targeted sequencing may use cfDNA to investigate defined gene panels.

Extraction should support:

• Sufficient library input;

• Broad fragment recovery;

• Low genomic contamination;

• Consistent insert-size profiles;

• Low inhibitor carryover.

NEB and Thermo Fisher both position their cfDNA extraction products for downstream sequencing as well as amplification.

Whole-Genome and Fragmentomic Analysis

Fragmentomic analysis examines properties such as:

• Fragment length;

• Fragment ends;

• Nucleosome patterns;

• Genome-wide distribution.

These workflows are especially sensitive to extraction-related size bias.

A method that selectively loses short or long fragments may distort the biological profile.

Methylation Analysis

cfDNA methylation studies require:

• Efficient recovery;

• Low degradation;

• Compatibility with conversion or enrichment chemistry;

• Controlled fragment bias.

The extraction buffer and elution solution must be compatible with the subsequent methylation workflow.

Noninvasive Prenatal Research

Cell-free fetal or placental DNA represents a fraction of maternal plasma cfDNA.

Extraction methods for this application should control:

• Maternal genomic DNA contamination;

• Short-fragment recovery;

• Plasma handling;

• Precision;

• Sample-to-sample variation.

Transplant and Organ-Injury Research

Donor-derived cfDNA and tissue-derived cfDNA may be studied as circulating biomarkers.

The extraction system should provide:

• Reproducible low-input recovery;

• Minimal fragment bias;

• Reliable sample processing;

• Compatibility with sensitive molecular detection.

How to Evaluate cfDNA Extraction Performance

Total yield

Use fluorescence-based quantification or molecular assays suited to low DNA concentrations.

UV absorbance may lack sufficient sensitivity and may be affected by contaminants.

Fragment-specific recovery

Measure recovery in selected size ranges using:

• Capillary electrophoresis;

• Fragment analyzers;

• qPCR assays of different lengths;

• Sequencing insert sizes.

Genomic DNA contamination

Evaluate the proportion of long DNA using:

• Long-fragment qPCR;

• Electrophoretic profiles;

• Genomic DNA controls;

• Sequencing metrics.

Functional performance

Test:

• qPCR;

• Digital PCR;

• Library-preparation yield;

• Sequencing quality;

• Variant detection using appropriate reference materials.

Precision

Evaluate:

• Within-run precision;

• Between-run precision;

• Operator variation;

• Instrument variation;

• Plate-position variation;

• Bead-lot variation.

Recovery near the detection limit

Low-input performance should be tested using multiple replicates near the intended analytical limit.

High-concentration samples alone cannot demonstrate suitability for liquid-biopsy applications.

Common Problems and Troubleshooting

SANYU Silica Magnetic Beads for cfDNA Method Development

SANYU supplies silica magnetic beads for nucleic acid extraction and purification through the Nanomicron Spheres platform.

The publicly listed beads use a superparamagnetic core with a silica-coated nucleic acid-binding surface. SANYU also states that particle size, concentration, surface properties and packaging can be customized for nucleic acid extraction and OEM development.

Potential role in cfDNA projects

SANYU silica magnetic beads may be screened as raw materials for:

• Plasma cfDNA extraction;

• Biofluid cell-free DNA extraction;

• Manual magnetic workflows;

• Automated extraction instruments;

• Liquid-biopsy research reagent development;

• OEM cfDNA extraction kits.

The standard silica magnetic bead product should not automatically be represented as a validated cfDNA reagent.

cfDNA compatibility must be established using application-specific testing because cfDNA extraction requires:

• Efficient short-fragment recovery;

• Low-concentration precision;

• Large biofluid-volume compatibility;

• Low genomic DNA bias;

• Small-volume elution;

• Low bead carryover.

Recommended SANYU screening process

Evaluate several suitable particle options using the same:

• Plasma pool;

• Binding buffer;

• Bead dose;

• Magnetic separator;

• Wash buffers;

• Elution conditions.

Compare:

• Total recovery;

• 50–150 bp recovery;

• 150–300 bp recovery;

• Long genomic DNA recovery;

• qPCR or digital PCR;

• Fragment profile;

• Bead carryover;

• Precision.

Custom and OEM requirements

Commercial customers can discuss:

• Particle diameter;

• Particle-size distribution;

• Magnetic response;

• Silica surface properties;

• Solids concentration;

• Suspension formulation;

• Packaging;

• Pilot supply;

• Commercial-volume manufacturing;

• OEM or private-label requirements.

The final bead specification should be tied to functional cfDNA recovery rather than physical particle data alone.

How to Choose a Silica Magnetic Bead Supplier

Evaluate the supplier in four areas.

Particle characterization

Request:

• Mean particle size;

• D10, D50 and D90;

• CV or PDI;

• Solids concentration;

• Magnetic content;

• Magnetic collection time;

• Sedimentation;

• Redispersibility.

cfDNA performance

Request or generate data for:

• Low-input DNA recovery;

• Short-fragment recovery;

• Typical nucleosomal-region recovery;

• Genomic DNA contamination;

• Small-volume elution;

• Bead carryover;

• Plasma compatibility.

Quality capability

Request:

• Certificate of Analysis;

• Safety Data Sheet;

• Product specification;

• Batch traceability;

• Stability information;

• Change-control policy;

• Lot-release criteria.

Commercial capability

Confirm:

• Sample availability;

• Pilot volume;

• Commercial capacity;

• Lead time;

• Reserved lots;

• Safety stock;

• Packaging;

• Supply continuity.

Validation Requirements for Commercial and IVD Development

A successful research experiment is not sufficient for a commercial liquid-biopsy extraction product.

Validation may need to address:

• Analytical recovery;

• Fragment-size bias;

• Precision;

• Reproducibility;

• Interference;

• Cross-contamination;

• Sample stability;

• Reagent stability;

• Instrument compatibility;

• Lot-to-lot consistency.

Preanalytical validation

Evaluate:

• Collection tubes;

• Processing delay;

• Transport;

• Plasma preparation;

• Storage;

• Freeze–thawing.

Analytical validation

Evaluate:

• Low-input recovery;

• Fragment-specific recovery;

• genomic DNA contamination;

• Inhibition;

• Elution concentration;

• Downstream assay performance.

Interference

Potential interferents may include:

• Hemoglobin;

• Lipids;

• Anticoagulants;

• High protein concentration;

• Collection-tube additives;

• Residual cells.

Cross-contamination

Use alternating high-positive and negative samples to challenge the workflow.

Stability

Test:

• Real-time stability;

• Accelerated stability;

• Open-bottle stability;

• Prefilled-plate stability;

• Transport stability.

Clinical or diagnostic claims require the applicable regulatory and analytical validation. Manufacturer research-use claims should not be extended beyond their documented intended use.

Information to Include in an RFQ

A cfDNA magnetic bead RFQ should include:

1. Intended cfDNA application;

2. Plasma, serum, urine, CSF or other biofluid;

3. Sample input volume;

4. Expected cfDNA concentration;

5. Required fragment-size range;

6. Required recovery below 100 bp;

7. Required recovery in the 150–300 bp region;

8. Maximum acceptable long genomic DNA recovery;

9. Manual or automated workflow;

10. Extraction instrument;

11. Magnetic rod or liquid-handler architecture;

12. Tube, cartridge or plate format;

13. Required samples per run;

14. Preferred particle size;

15. Required magnetic collection time;

16. Bead concentration;

17. Binding-buffer chemistry;

18. Wash-buffer chemistry;

19. Elution volume;

20. qPCR, digital PCR or NGS downstream method;

21. Minimum recovery requirement;

22. Maximum bead carryover;

23. Precision requirement;

24. Sample quantity;

25. Pilot order;

26. Estimated annual demand;

27. Packaging requirement;

28. Required quality documents;

29. Shelf-life target;

30. OEM or private-label requirement.

Frequently Asked Questions

What are silica magnetic beads used for in liquid biopsy?

They are used to isolate cfDNA from plasma or other biofluids before PCR, digital PCR, sequencing or other molecular analyses.

Is cfDNA the same as ctDNA?

No. ctDNA is the tumor-derived fraction of cfDNA.

Does extracting more total DNA mean recovering more ctDNA?

Not necessarily. A high total yield may include genomic DNA released from blood cells.

Why is plasma usually preferred to serum?

Serum preparation may release additional genomic DNA during clotting and cellular disruption, increasing background contamination.

What size is cfDNA?

cfDNA commonly shows nucleosome-associated fragment patterns, but it includes a range of shorter and longer fragments. The required recovery range depends on the application.

Why are short cfDNA fragments difficult to extract?

They may be present at low concentration and may bind differently from long genomic DNA under some extraction conditions.

Can silica magnetic beads recover DNA below 100 bp?

Some optimized bead and buffer systems can recover ultrashort fragments, but this capability must be demonstrated for the specific formulation.

Are smaller magnetic beads always better for cfDNA?

No. Smaller beads may provide more surface area but can collect more slowly and increase bead carryover.

Can magnetic beads extract cfDNA from serum?

Yes, validated systems can process serum, but plasma is usually preferred for ctDNA-related workflows.

Can cfDNA be extracted from urine or CSF?

Yes. Commercial magnetic bead systems are available for urine and cerebrospinal fluid, but each matrix requires separate validation.

Can magnetic bead extraction be automated?

Yes. cfDNA extraction can be automated using magnetic rod instruments, liquid handlers or cartridge systems.

What is the best elution volume?

There is no universal volume. Smaller volumes improve concentration, while larger volumes may improve total recovery.

What causes genomic DNA contamination?

Common causes include delayed blood processing, white blood cell disruption and accidental transfer of the buffy coat.

What causes low cfDNA yield?

Possible causes include incomplete protein digestion, inadequate binding chemistry, poor bead mixing, short-fragment loss and inefficient elution.

How should cfDNA yield be measured?

Use sensitive fluorescence or molecular methods and evaluate fragment-specific recovery. UV absorbance alone may be unreliable at low concentrations.

Is cfDNA extraction the same as size selection?

No. Extraction recovers cfDNA from the original biofluid. Size selection enriches or removes particular DNA fragment ranges after or during purification.

Can the same workflow use silica and carboxyl magnetic beads?

Yes. Silica beads may extract cfDNA, while carboxylated SPRI beads may subsequently clean or size-select the sequencing library.

Does SANYU supply silica magnetic beads for cfDNA extraction?

SANYU supplies silica magnetic beads for nucleic acid extraction. Their suitability for cfDNA must be established through short-fragment, low-input and plasma-specific validation.

Conclusion

Silica magnetic beads provide a flexible solid phase for isolating cell-free DNA from plasma and other biofluids.

Their main advantages include:

• High accessible binding surface;

• Magnetic separation without centrifugation;

• Flexible sample input;

• Small-volume elution;

• Manual and automated compatibility;

• Scalability for liquid-biopsy workflows.

However, cfDNA extraction is more demanding than routine genomic DNA extraction.

The target is often:

• Low in concentration;

• Highly fragmented;

• Mixed with abundant proteins;

• Contaminated by cellular genomic DNA;

• Sensitive to collection and processing conditions.

A successful workflow must control:

• Blood collection;

• Plasma preparation;

• Protein digestion;

• Short-fragment binding;

• Wash efficiency;

• Alcohol removal;

• Elution;

• Fragment-size bias;

• Bead carryover.

Total DNA yield alone is not sufficient.

The method should also be evaluated for:

• Recovery below 150 bp;

• Recovery in the typical nucleosomal cfDNA region;

• Long genomic DNA contamination;

• qPCR or digital PCR performance;

• NGS library quality;

• Precision near the detection limit.

SANYU supplies silica magnetic beads that may be screened as raw materials for cfDNA extraction and liquid-biopsy research reagent development.

The final product should be selected using the actual:

• Plasma or biofluid matrix;

• Sample input volume;

• Binding chemistry;

• Magnetic separator;

• Elution volume;

• Fragment-size requirement;

• Downstream molecular assay.

A structured validation process covering preanalytics, short-fragment recovery, genomic DNA contamination, precision, interference, stability and lot consistency provides the most reliable route from silica magnetic bead screening to a scalable cfDNA extraction workflow.